An Antibody-armored Dendritic Cell in Patients With Solid Tumors

Inclusion Criteria: * Aged 18 to 80 years, body weight ≥ 40 kg; male or female, no gender restriction; * ECOG performance status score of 0 to 1; * Histopathologically confirmed solid tumors including pancreatic cancer, colorectal cancer (CRC), gastric cancer and other such malignancies; * Having undergone R0 or R1 resection with completion of at least 4 cycles of standard postoperative adjuvant chemotherapy; * Positive expression for at least one of TERT, P53, KRAS and Survivin; * Sufficient venous access with no contraindications to peripheral blood mononuclear cell collection; * Adequate organ and bone marrow function: * a) Platelet count ≥ 90×10⁹/L; * b) Hemoglobin ≥ 90 g/L (no blood transfusion or erythropoietin dependence within 7 days); * c) Mononuclear cell count ≥ 1.0×10⁹/L; * d) International Normalized Ratio (INR) or Prothrombin Time (PT) ≤ 1.5 × upper limit of normal (ULN); * e) Serum creatinine ≤ 1.5 × upper limit of normal (ULN); * f) Aminotransferases (AST, ALT) ≤ 2.5 × upper limit of normal (ULN); * g) Total bilirubin ≤ 2 × upper limit of normal (ULN); * h) Cardiac function: Left Ventricular Ejection Fraction (LVEF) ≥ 50% as assessed by echocardiography within 1 month prior to enrollment; * Able to understand the study requirements and considerations and provide informed consent to participate in the clinical study in accordance with the study requirements * Subjects agree to use effective contraceptive measures for at least 6 months following dendritic cell (DC) injection. Exclusion Criteria: * Women who are pregnant or breastfeeding; * Positive for human immunodeficiency virus (HIV) antibody or syphilis antibody; positive for hepatitis B surface antigen (HBsAg), positive for hepatitis B core antibody (anti-HBc) or hepatitis B e antibody (anti-HBe) with hepatitis B virus (HBV) DNA copy number above the lower limit of detection (LLOD) or ≥ 1000 copies/mL; or hepatitis C virus (HCV) RNA copy number above the LLOD; * Prior treatment with any dendritic cell (DC) or other immune cell therapy; * History of hypersensitivity to immunotherapy and related drugs, or history of severe allergic reactions; * Uncontrolled active infection; * Subjects with active autoimmune disease receiving relevant treatment; subjects with organ transplantation who are still on immunosuppressive agents; or subjects requiring long-term use of immunosuppressive agents (\> 15 mg/day prednisone or equivalent glucocorticoid dose) and who have used them within 4 weeks prior to screening; * Presence of central nervous system (CNS) metastases and clinically significant CNS diseases; * Received systemic anti-tumor therapy within 4 weeks prior to screening; * Presence of residual lesions or unremoved foci on screening examinations (post-adjuvant chemotherapy / post-surgery), with imaging indicating local recurrence or confirmed distant metastasis; * History of other active malignancies within 5 years (excluding cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, etc.); * Clinically significant major cardiovascular diseases including: * a) Symptomatic congestive heart failure * b) Unstable angina pectoris * c) Severe arrhythmia requiring pharmacotherapy * d) Uncontrolled hypertension * e) Myocardial infarction or ventricular arrhythmia within 6 months prior to screening; * Any other conditions deemed by the investigator to render the subject ineligible for participation in the clinical study